|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Vaughan S, Coward JI, Bast RC Jr, Berchuck
A, Berek JS, Brenton JD, Coukos G, Crum CC, Drapkin R,
Etemadmoghadam D, et al: Rethinking ovarian cancer: Recommendations
for improving outcomes. Nat Rev Cancer. 11:719–725. 2011.PubMed/NCBI View
Article : Google Scholar
|
|
3
|
Weidle UH, Dickopf S, Hintermair C,
Kollmorgen G, Birzele F and Brinkmann U: The role of micro RNAs in
breast cancer metastasis: Preclinical validation and potential
therapeutic targets. Cancer Genomics Proteomics. 15:17–39.
2018.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Jiang YW and Chen LA: microRNAs as tumor
inhibitors, oncogenes, biomarkers for drug efficacy and outcome
predictors in lung cancer (review). Mol Med Rep. 5:890–894.
2012.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Kelly BD, Miller N, Healy NA, Walsh K and
Kerin MJ: A review of expression profiling of circulating microRNAs
in men with prostate cancer. BJU Int. 111:3–4. 2013.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Nair VS, Maeda LS and Ioannidis JP:
Clinical outcome prediction by microRNAs in human cancer: A
systematic review. J Natl Cancer Inst. 104:528–540. 2012.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Iorio MV and Croce CM: MicroRNAs in
cancer: Small molecules with a huge impact. J Clin Oncol.
27:5848–5856. 2009.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Glud M, Rossing M, Hother C, Holst L,
Hastrup N, Nielsen FC, Gniadecki R and Drzewiecki KT:
Downregulation of miR-125b in metastatic cutaneous malignant
melanoma. Melanoma Res. 20:479–484. 2010.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Bushati N and Cohen SM: microRNA
functions. Annu Rev Cell Dev Biol. 23:175–205. 2007.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Croce CM: Causes and consequences of
microRNA dysregulation in cancer. Nat Rev Genet. 10:704–714.
2009.PubMed/NCBI View
Article : Google Scholar
|
|
11
|
Yin W, Nie Y, Chen L, Wang Q, Liu S, He X
and Wang W: Deregulation of microRNA-193b affects the proliferation
of liver cancer via myeloid cell leukemia-1. Oncol Lett.
15:2781–2788. 2018.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Wu H and Zhou C: Long non-coding RNA UCA1
promotes lung cancer cell proliferation and migration via
microRNA-193a/HMGB1 axis. Biochem Biophys Res Commun. 496:738–745.
2018.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Fang C, Dai CY, Mei Z, Jiang MJ, Gu DN,
Huang Q and Tian L: microRNA-193a stimulates pancreatic cancer cell
repopulation and metastasis through modulating TGF-β2/TGF-βRIII
signalings. J Exp Clin Cancer Res. 37(25)2018.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Chan CM, Lai KKY, Ng EKO, Kiang MN, Kwok
TWH, Wang HK, Chan KW, Law TT, Tong DK, Chan KT, et al: Serum
microRNA-193b as a promising biomarker for prediction of
chemoradiation sensitivity in esophageal squamous cell carcinoma
patients. Oncol Lett. 15:3273–3280. 2018.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Han D, Wang J and Cheng G: LncRNA NEAT1
enhances the radio-resistance of cervical cancer via
miR-193b-3p/CCND1 axis. Oncotarget. 9:2395–2409. 2017.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Chan JK, Cheung MK, Husain A, Teng NN,
West D, Whittemore AS, Berek JS and Osann K: Patterns and progress
in ovarian cancer over 14 years. Obstet Gynecol. 108:521–528.
2006.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Fabbri M, Ivan M, Cimmino A, Negrini M and
Calin GA: Regulatory mechanisms of microRNAs involvement in cancer.
Expert Opin Biol Ther. 7:1009–1019. 2007.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Croce CM and Calin GA: miRNAs, cancer, and
stem cell division. Cell. 122:6–7. 2005.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Brown JR and Sanseau P: A computational
view of microRNAs and their targets. Drug Discov Today. 10:595–601.
2005.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Tahiri A, Leivonen SK, Lüders T, Steinfeld
I, Ragle Aure M, Geisler J, Mäkelä R, Nord S, Riis ML, Yakhini Z,
et al: Deregulation of cancer-related miRNAs is a common event in
both benign and malignant human breast tumors. Carcinogenesis.
35:76–85. 2014.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Zhou H, Wang K, Hu Z and Wen J: TGF-β1
alters microRNA profile in human gastric cancer cells. Chin J
Cancer Res. 25:102–111. 2013.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Cheung TH, Man KN, Yu MY, Yim SF, Siu NS,
Lo KW, Doran G, Wong RR, Wang VW, Smith DI, et al: Dysregulated
microRNAs in the pathogenesis and progression of cervical neoplasm.
Cell Cycle. 11:2876–2884. 2012.PubMed/NCBI View
Article : Google Scholar
|
|
23
|
Xie C, Jiang XH, Zhang JT, Sun TT, Dong
JD, Sanders AJ, Diao RY, Wang Y, Fok KL, Tsang LL, et al: CFTR
suppresses tumor progression through miR-193b targeting urokinase
plasminogen activator (uPA) in prostate cancer. Oncogene.
32:2282–2291. 2013.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Wu W, Lin Z, Zhuang Z and Liang X:
Expression profile of mammalian microRNAs in endometrioid
adenocarcinoma. Eur J Cancer Prev. 18:50–55. 2009.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Rauhala HE, Jalava SE, Isotalo J, Bracken
H, Lehmusvaara S, Tammela TL, Oja H and Visakorpi T: miR-193b is an
epigenetically regulated putative tumor suppressor in prostate
cancer. Int J Cancer. 127:1363–1372. 2010.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Chen J, Feilotter HE, Paré GC, Zhang X,
Pemberton JG, Garady C, Lai D, Yang X and Tron VA: MicroRNA-193b
represses cell proliferation and regulates cyclin D1 in melanoma.
Am J Pathol. 176:2520–2529. 2010.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Li H, Xu Y, Qiu W, Zhao D and Zhang Y:
Tissue miR-193b as a novel biomarker for patients with ovarian
cancer. Med Sci Monit. 21:3929–3934. 2015.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Kueh HY and Mitchison TJ: Structural
plasticity in actin and tubulin polymer dynamics. Science.
325:960–963. 2009.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Rana S, Maples PB, Senzer N and Nemunaitis
J: Stathmin 1: A novel therapeutic target for anticancer activity.
Expert Rev Anticancer Ther. 8:1461–1470. 2008.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Rubin CI and Atweh GF: The role of
stathmin in the regulation of the cell cycle. J Cell Biochem.
93:242–250. 2004.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Belletti B and Baldassarre G: Stathmin: A
protein with many tasks. New biomarker and potential target in
cancer. Expert Opin Ther Targets. 15:1249–1266. 2011.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Mistry SJ and Atweh GF: Role of stathmin
in the regulation of the mitotic spindle: Potential applications in
cancer therapy. Mt Sinai J Med. 69:299–304. 2002.PubMed/NCBI
|
|
33
|
Ke B, Wu LL, Liu N, Zhang RP, Wang CL and
Liang H: Overexpression of stathmin 1 is associated with poor
prognosis of patients with gastric cancer. Tumour Biol.
34:3137–3145. 2013.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Tamura K, Yoshie M, Miyajima E, Kano M and
Tachikawa E: Stathmin regulates hypoxia-inducible factor-1α
expression through the mammalian target of rapamycin pathway in
ovarian clear cell adenocarcinoma. ISRN Pharmacol.
2013(279593)2013.PubMed/NCBI View Article : Google Scholar
|
